Zusammenfassung
Patienten in der akuten Phase nach ischämischem Insult haben eine erhöhte Inzidenz von Beinvenenthrombosen und Lungenembolien, die die Genesung verzögern und zu einer erhöhten Morbidität und Mortalität dieser Patienten beitragen. Lungenembolien sind eine wichtige Todesursache von Patienten nach ischämischem Schlaganfall. Während die Plättchenhemmung mit z. B. Azetylsalizylsäure (ASS) heute zur Standardtherapie der frühen Rezidivprophylaxe beim Schlaganfall gehört, wird die Dauer und die Dosierung sowie die Substanz (unfraktioniertes versus niedermolekulares Heparin) nicht aber die Notwendigkeit einer Antikoagulation zur Thromboembolieprophylaxe kontrovers diskutiert. Plazebo- oder ASS-kontrollierte Studien mit Heparinen - überwiegend in PTT-wirksamer Dosis - zeigten eine Reduktion früher Reinfarkte. Allerdings ging dieser positive Effekt zulasten einer erhöhten zerebralen Blutungsrate, sodass keine allgemeine Empfehlung für eine PTT-wirksame Heparinisierung ausgesprochen werden konnte. Alle Studien mit niedrigen oder hohen Heparindosen zeigten aber eine Reduktion des Risikos von tiefen Beinvenenthrombosen. Neuere Vergleichsstudien von niedermolekularen Heparinen (Enoxaparin, Certoparin) mit unfraktionierten Heparinen zeigten in den letzten Jahren die Bedeutung einer frühzeitigen Antikoagulation innerhalb der ersten 48 Stunden nach Insult. Deren Anwendung ist mit einer Senkung thromboembolischer Ereignisse bei gleichzeitig unverändertem Blutungsrisiko gegenüber unfraktioniertem Heparin verbunden. Darüber hinaus ist die Anwendung niedermolekularer Heparine mit einer vereinfachten Handhabung ein praktisch gut umsetzbares Therapieprinzip. Die Prophylaxe thromboembolischer Komplikationen mit niedermolekularen Heparinen wird somit bei Patienten nach ischämischem Schlaganfall empfohlen.
Abstract
Patients in the acute phase after ischaemic insult have an increased incidence of venous thrombosis in the leg and pulmonary embolism which delay recovery and contribute to a higher morbidity and mortality for these patients. Pulmonary embolism is an important cause of death in patients after ischaemic stroke. Although platelet inhibition with, e. g., acetylsalicylic acid (ASA), constitutes the standard therapy for prophylaxis against early recurrence in stroke patients, the duration and doses as well as the substances (unfractionated versus low molecular heparin), but not the necessity for anticoagulation as prophylaxis against thromboemolism, are currently a subject of controversy. Placebo- or ASA-controlled studies with heparins, mainly in PTT-effective doses, were often not clinically unambiguous in practice and showed a reduction of early reinfarctions at the cost of cerebral haemorrhage. However, all studies with low or high doses of heparin showed a reduced risk for deep vein thrombosis of the legs. New comparative studies of low-molecular heparins (Enoxaparin, Certoparin) with unfractionated have shown in recent years the significance of early anticoagulation within the first 48 hours after the insult. Their use is associated with a reduction of thromboembolic events with a concomitant unchanged risk of haemorrhage in comparison with unfractionated heparin. Furthermore, the administration of low-molecular heparins with their simple use constitutes a practical and easily applicable therapeutic principle. It can be recommended as a prophylaxis against thromboembolic complications in these patients.
Schlüsselwörter
Enoxaparin - Certoparin - tiefe Beinvenenthrombose - Lungenembolie - Schlaganfall
Key words
enoxaparin - certoparin - deep vein thrombosis - pulmonary embolism - stroke
Literatur
-
1
Warlow C P.
Epidemiology of stroke.
Lancet.
1998;
352, Suppl 3
SIII1-4
-
2
Kay R. et al .
Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry.
Neurology.
1992;
42
985-987
-
3
Carandang R. et al .
Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years.
JAMA.
2006;
296
2939-2946
-
4
Kolominsky-Rabas P L. et al .
Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project.
Stroke.
2006;
37
1179-1183
-
5
Turpie A G.
Prophylaxis of venous thromboembolism in stroke patients.
Semin Thromb Hemost.
1997;
23
155-157
-
6
Lensing A W.
Anticoagulation in acute ischaemic stroke: deep vein thrombosis prevention and long-term stroke outcomes.
Blood Coagul Fibrinolysis.
1999;
10, Suppl 2
S123-127
-
7
Kelly J, Rudd A, Lewis R, Hunt B J.
Venous thromboembolism after acute stroke.
Stroke.
2001;
32
262-267
-
8
Geerts W H. et al .
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest.
2004;
126
338S-400S
-
9
Leizorovicz A, Mismetti P.
Preventing venous thromboembolism in medical patients.
Circulation.
2004;
110
IV13-19
-
10
Svigelj V, Steblaj S, Grad A.
Low-dose subcutaneous heparin decreases mortality from pulmonary embolism in patients with ischemic stroke.
Neurol Croat.
1991;
40
23-29
-
11
Kelly J. et al .
Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging.
Stroke.
2004;
35
2320-2325
-
12
Bounds J V, Wiebers D O, Whisnant J P, Okazaki H.
Mechanisms and timing of deaths from cerebral infarction.
Stroke.
1981;
12
474-477
-
13
Brown M, Glassenberg M.
Mortality factors in patients with acute stroke.
JAMA.
1973;
224
1493-1495
-
14
Heuschmann P U. et al .
Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group.
Arch Intern Med.
2004;
164
1761-1768
-
15
Viitanen M, Winblad B, Asplund K.
Autopsy-verified causes of death after stroke.
Acta Med Scand.
1987;
222
401-408
-
16
Diener H C. et al .
Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
Stroke.
2006;
37
139-144
-
17
Hillbom M. et al .
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
Acta Neurol Scand.
2002;
106
84-92
-
18
Sherman D G. et al .
The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
Lancet.
2007;
369
1347-1355
-
19
CAST (Chinese Acute Stroke Trial) Collaborative Group .
CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke.
Lancet.
1997;
349
1641-1649
-
20
International Stroke Trial Collaborative Group .
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke.
Lancet.
1997;
349
1569-1581
-
21
Adams Jr H P. et al .
Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association.
Stroke.
2003;
34
1056-1083
-
22
Albers G W. et al .
Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest.
2004;
126
483S-512S
-
23
Adams H, Adams R, Del Zoppo G, Goldstein L B.
Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association.
Stroke.
2005;
36
916-923
-
24 Diener H C, Putzki N, Berlit P. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Georg Thieme Verlag KG 2005
-
25
Andre C, de Freitas G R, Fukujima M M.
Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles.
Eur J Neurol.
2007;
14
21-32
-
26
Kamphuisen P W, Agnelli G, Sebastianelli M.
Prevention of venous thromboembolism after acute ischemic stroke.
J Thromb Haemost.
2005;
3
1187-1194
-
27
Prins M H. et al .
Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients.
Haemostasis.
1989;
19
245-250
-
28
Sandset P M. et al .
A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke.
Semin Thromb Hemost.
1990;
16, Suppl
25-33
-
29
Kay R. et al .
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
N Engl J Med.
1995;
333
1588-1593
-
30
Bath P M. et al .
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Lancet.
2001;
358
702-710
-
31
Bath P M, Iddenden R, Bath F J.
Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials.
Stroke.
2000;
31
1770-1778
-
32 Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev 2002 CD003242
-
33 Sandercock P, Counsell C, Stobbs S L. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2005 CD000119
-
34
Berge E, Abdelnoor M, Nakstad P H, Sandset P M.
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Lancet.
2000;
355
1205-1210
-
35
Sherman D G, Soltes S, Samuel R, Chibedi-Deroche D.
Enoxaparin versus unfractionated Heparin in the prevention of venous thromboembolism after acute ischemic stroke: Rationale, design, and methods of an open-label, randomized, parallel-group multicenter trial.
J Stroke Cerebrovas Dis.
2005;
14
95-100
-
36
Diener H C. et al .
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
Stroke.
2001;
32
22-29
-
37
Hommel M. for the FISS bis Investigators Group .
Fraxiparine in ischaemic stroke study (FISS bis). Abstract.
Cerebrovasc Dis.
1998;
8
19
-
38
Harvey R L, Lovell L L, Belanger N, Roth E J.
The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation: a historical cohort study.
Arch Phys Med Rehabil.
2004;
85
1070-1075
-
39
Schadlich P K. et al .
Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Pharmacoeconomics.
2006;
24
571-591
-
40
Kalafut M A, Gandhi R, Kidwell C S, Saver J L.
Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia.
Stroke.
2000;
31
2563-2568
-
41
Warlow C, Ogston D, Douglas A S.
Venous thrombosis following strokes.
Lancet.
1972;
1
1305-1306
-
42
Warlow C, Ogston D, Douglas A S.
Deep venous thrombosis of the legs after strokes. Part I - incidence and predisposing factors.
Br Med J.
1976;
1
1178-1181
-
43
McCarthy S T. et al .
Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke.
Lancet.
1977;
2
800-801
-
44
McCarthy S T, Turner J.
Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.
Age Ageing.
1986;
15
84-88
-
45
Turpie A G. et al .
Double-blind randomised trial of Org 10 172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
Lancet.
1987;
1
523-526
-
46
Elias A. et al .
Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients).
Rev Med Interne.
1990;
11
95-98
-
47
Pambianco G, Orchard T, Landau P.
Deep vein thrombosis: prevention in stroke patients during rehabilitation.
Arch Phys Med Rehabil.
1995;
76
324-330
-
48
The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators .
Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial.
JAMA.
1998;
279
1265-1272
Prof. Dr. Hans-Christoph Diener
Universitätsklinik Essen, Klinik für Neurologie
Hufelandstr. 55
45147 Essen
eMail: hans.diener@uni-duisburg-essen.de
